Advertisement

Topics

FDA Approves Amgen and Novartis Migraine Drug Aimovig, Expected to Be Ready for Patients in 1 Week

20:00 EDT 17 May 2018 | BioSpace

Amgen and Novartis scored a big win in the migraine market late Thursday when the U.S. Food and Drug Administration approved Aimovig (erenumab-aooe) for the preventive treatment of migraine in adults.

Original Article: FDA Approves Amgen and Novartis Migraine Drug Aimovig, Expected to Be Ready for Patients in 1 Week

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Amgen and Novartis Migraine Drug Aimovig, Expected to Be Ready for Patients in 1 Week"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...